Evaluation of the effect of traditional Chinese medicine on the treatment of patients with COVID-19 infection

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059740

Enrollment

Unknown

Registered

2022-05-10

Start date

2022-05-05

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Experimental group:Jingyin Gubiao granules, twice a day, one sachet each time, orally after meals

Control group:blank control

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Meet the discharge criteria for patients infected with novel coronavirus pneumonia and stay in home health isolation for 7 days; 2. Age 18-85 years old, gender is not limited; 3. Patients voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the inclusion criteria; 2. People with severe cardiovascular and cerebrovascular diseases; 3. Mentally ill patients; 4. Those who are allergic to the medicinal ingredients contained in traditional Chinese medicine; 5. Pregnant women; 6. Those who have poor compliance and cannot cooperate with the treatment.

Design outcomes

Primary

Measure	Time frame
COVID-19 nucleic acid;	—

Countries

China

Contacts

Public ContactHao Weiwei

Shuguang Hospital Affiliated of Shanghai University of Traditional Chinese Medicine

hwwwork@163.com+86 18917763158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026